logo
logo

Idrx Launches With $122 Million Series A Financing To Treat Cancer With Purpose-Built Precision Combination Therapies

Idrx Launches With $122 Million Series A Financing To Treat Cancer With Purpose-Built Precision Combination Therapies

08/02/22, 10:35 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgplymouth
Money raised
$122 million
Industry
health care
therapeutics
pharmaceutical
biotechnology
Round Type
series a
IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed Series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered in other disease areas such as cystic fibrosis and antivirals, IDRx was incubated by Borisy Labs to address the limitations of today’s precision cancer medicines with highly selective, purposely designed drug combinations to help more patients achieve prolonged, durable responses to therapy earlier in the course of their disease.

Company Info

Company
IDRx
Location
plymouth, massachusetts, united states
Additional Info
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s lead program is IDRX-42, designed to inhibit key genetic drivers and drug-resistant mutations of KIT in gastrointestinal stromal tumor (GIST). IDRx's pipeline also includes a second KIT inhibitor, IDRX-73. Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development, and commercialization of more than 10 approved drugs.

Related People